Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Cellectar Biosciences (NASDAQ: CLRB) will report full year financial results for the period ended December 31, 2025, and host a corporate update and conference call on Wednesday, March 4, 2026 at 8:30 a.m. Eastern Time.

Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) will report full year financial results for the period ended December 31, 2025, and host a corporate update and conference call on Wednesday, March 4, 2026 at 8:30 a.m. Eastern Time.

The event will be accessible by toll-free dial-in and webcast; a replay of the presentation will be available on the company’s Investor Relations Events page.

Argus Feb 25 session

+3.57% close to close Open Argus

Details

News Market Reaction – CLRB

In the Feb 25 session, CLRB gained 3.57%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Cellectar’s full-year 2025 financial results and corporate ...

Analysis

This announcement sets the timetable for Cellectar’s full-year 2025 financial results and corporate update on March 4, 2026 at 8:30 a.m. ET. It follows a prior Q3 2025 call notice that coincided with a modest +2.69% move. Investors may focus on updates to cash runway, any new financing steps, and progress for iopofosine I 131 and other programs discussed on the call, given recent regulatory filings emphasizing both pipeline advancement and liquidity risk.

Key Figures

Full year period end: December 31, 2025 Earnings call date: March 4, 2026 Call time: 8:30 a.m. Eastern Time +2 more

Full year period end

December 31, 2025

Financial results period referenced in call announcement

Earnings call date

March 4, 2026

Scheduled full-year 2025 results and corporate update

Call time

8:30 a.m. Eastern Time

Start time for conference call and webcast

Toll-free dial-in

1-800-717-1738

Investor access number for the conference call

Conference ID

08197

Identifier for accessing the webcast/call

Previous Conferences,earnings date Reports

1 past event · Latest: Nov 06

Same Type 1 event

1. Nov 06

   Earnings date notice

   24h Move

   +2.7%

   Announced Q3 2025 results date and investor conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time.

Conference Call & Webcast Details:
Date:	Wednesday, March 4, 2026
Time:	8:30 am Eastern Time
Toll Free:	1-800-717-1738
Conference ID: Webcast:	08197 Click HERE

A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical radiopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments that deliver improved efficacy and better safety.

The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope) for the treatment of hematologic and solid tumor cancers such as Waldenstrom’s macroglobulinemia (WM) and pediatric high grade gliomas; CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeting solid tumors, such as triple negative breast, lung and colorectal cancers; CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors with significant unmet need, such as pancreatic cancer; and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

Iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory WM and multiple myeloma (MM), non-Hodgkin’s lymphomas and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough Therapy, six Orphan Drug, five Rare Pediatric Drug and two Fast Track Designations for various cancer indications. The European Medicines Agency (EMA) has also granted iopofosine I 131 PRIME and orphan drug designations for the treatment of WM.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.

Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cellectar Biosciences (CLRB) report full year 2025 financial results and hold its conference call?

The company will report results and host the call on Wednesday, March 4, 2026 at 8:30 a.m. Eastern Time. According to Cellectar Biosciences, the announcement covers the full year ended December 31, 2025, and includes a corporate update during the call.

How can investors access the Cellectar Biosciences (CLRB) March 4, 2026 conference call and webcast?

Investors can join via the toll-free number or the company webcast with Conference ID 08197. According to Cellectar Biosciences, the toll-free dial-in is 1-800-717-1738 and a webcast link is provided on the events page.

Will a replay of the Cellectar Biosciences (CLRB) presentation from March 4, 2026 be available for later viewing?

Yes, a replay of the corporate presentation will be available on the company's Investor Relations Events page. According to Cellectar Biosciences, investors can access the archived webcast after the live event for on-demand viewing.

What topics will Cellectar Biosciences (CLRB) cover during the March 4, 2026 corporate update?

The company will provide a corporate update alongside full year financial results during the call. According to Cellectar Biosciences, the update is part of the March 4, 2026 presentation, though detailed agenda items were not specified in the announcement.

What is the conference call dial-in information for Cellectar Biosciences (CLRB) on March 4, 2026?

The toll-free dial-in is 1-800-717-1738 and the webcast Conference ID is 08197. According to Cellectar Biosciences, callers should use the provided number and Conference ID to access the live call at 8:30 a.m. Eastern Time.

Is the March 4, 2026 Cellectar Biosciences (CLRB) event expected to include clinical program updates?

The announcement notes a corporate update will accompany full year results, which may include program information. According to Cellectar Biosciences, specifics were not detailed, so investors should listen to the March 4, 2026 call for substantive clinical updates.